查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830971

不孕不孕檢測市場

Infertility Testing Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

不孕症檢測市場預計將從 2024 年的 5.0029 億美元擴大到 2031 年的 8.9096 億美元，2025-2031 年期間的複合年成長率預計為 8.6%。

市場洞察與分析師觀點：男性和女性不孕症發病率的上升以及不孕症檢測技術的進步推動了市場的成長。然而，市場擴張受到認知度不足和不孕症檢測試劑盒限制的阻礙。

生殖健康領域的不孕症是指不會損害身體功能或構成生命危險，但卻會影響個人發展並導致個人（男性和女性）沮喪的疾病。大約有 5,000 萬到 8,000 萬對夫婦在其育齡期間至少會面臨一次不孕不育的挑戰。發展中國家和已開發國家之間的不孕症盛行率有所不同。世界衛生組織 (WHO) 報告稱，六分之一的夫婦患有不孕症問題。人們對檢測的認知不斷提高，加上生活方式的改變和不健康的飲食趨勢會導致不孕症和婦科疾病，這些因素正在推動不孕症檢測市場的擴張。此外，排卵監測技術的進步也進一步推動了市場的成長。菸草和吸菸消費的增加預計會提高不孕不育率，從而增加對不孕症檢測的需求。此外，生育意識的增強、受多囊性卵巢症候群影響的女性人數的增加、兩性對自我檢測和遠端監控的需求不斷成長以及創新產品的推出，都可能為預測期內的不孕症檢測市場創造機會。

成長動力：男性和女性不孕症發病率上升推動市場成長男性不孕症是全球普遍存在的問題，不同地區的盛行率各不相同。世界衛生組織指出，約 20% 的不孕夫婦有男性相關的不孕問題，而 30% 的夫婦則面臨雙方共同的不孕症挑戰。導致男性不孕的關鍵因素包括腦下垂體激素水平低、精液缺陷和品質差、影響精液進入陰道的性功能障礙以及存在精子抗體。美國衛生與公眾服務部稱，精索靜脈曲張（睪丸靜脈擴張）是精子數量低的最常見原因，影響約 40% 的不孕男性。男性不孕症病例的增加推動了對不孕檢測的需求。

在全球範圍內，由於晚婚和與年齡相關的不孕症等多種因素，生育率正在下降。世界衛生組織估計，2020年全球15至49歲成年人中約有1.285億新發衣原體感染病例，女性盛行率為4.0%，男性盛行率為2.5%。美國疾病管制與預防中心（CDC）報告稱，美國約有10%（610萬）15至44歲女性在懷孕或維持妊娠方面遇到困難。因此，生育率下降推動了對不孕症檢測的需求，以確定男性和女性不孕不育的原因，從而推動市場成長。

策略洞察報告細分和範圍：「不孕症檢測市場分析」是透過檢查以下細分進行的：類型、測試套件、樣本和最終用戶。

細分分析：不孕症檢測市場分為男性不孕症檢測和女性不孕症檢測。 2022年，女性不孕症檢測佔據了更大的市場佔有率，而男性不孕症檢測預計在預測期內將實現9.2%的複合年成長率。壓力增加、肥胖、吸煙和飲酒等因素會導致男性不孕不育。此外，人們對不孕症的認知不斷提高、研發支出增加、主要參與者推出新產品的舉措以及生活方式的改變，都在推動男性不孕症檢測領域的成長。

就檢測試劑盒而言，不孕症檢測市場分為人類卵泡刺激素 (FSH) 檢測試劑盒、人類絨毛膜促性腺激素 (HCG) 檢測試劑盒、黃體生成素 (LH) 檢測試劑盒等。人類卵泡刺激素 (FSH) 檢測試劑盒細分市場在 2022 年佔據最大市場佔有率，預計在預測期內將錄得 9.2% 的最高複合年成長率。 FSH 檢測試劑盒可測量血液中的 FSH 荷爾蒙濃度，這對於評估生育問題、更年期和性發育問題至關重要。 FSH 調節女性的月經週期和男性的精子生成，使其成為生殖健康的重要診斷工具。此外，生物相似藥 FSH 產品的進步、監管部門的批准以及 FSH 試劑盒生產的技術創新預計將推動全球市場成長。

依樣本類型，不孕症檢測市場可細分為血液、尿液和其他樣本。血液樣本在2022年佔據最大市場佔有率，預計在預測期內將達到9.1%的最高複合年成長率。不孕症檢測通常涉及血液檢測以測量關鍵激素，男性和女性根據其具體情況需要進行不同的檢測。 2021年1月，健康新創公司Yesmom推出了亞洲首款家用女性生育力血液檢測試劑盒，讓女性能方便地專注於生殖健康。

依終端用戶分類，不孕症檢測市場分為醫院和診所、生育中心和家庭護理。家庭護理領域在2022年佔據了最大的市場佔有率，預計在預測期內將實現9.0%的最高複合年成長率。這一成長歸因於患者對自我監測健康狀況的偏好、透過電商平台輕鬆獲取生育檢測試劑盒、方便用戶使用型設備的普及以及對檢測結果保密性的日益成長的需求。

輔助生殖技術 (ART) 和體外受精 (IVF) 的採用將推動不孕症檢測市場的發展。隨著人們對不孕症問題的認知不斷提高，未來幾年 IVF 和 ART 治療的需求可能會持續成長。先進的卵胞漿內單精子注射技術的引入，以及人們對藥物和手術 IVF 程序的認知度不斷提升，預計將在預測期內推動不孕症檢測市場的發展。根據加州大學舊金山分校健康中心的數據，約 10% 的不孕症病例歸因於不明原因，而 30% 的不孕症病例則與伴侶雙方的問題有關。

男性常見的治療手段包括卵胞漿內單一精子注射 (ICSI)、附睪穿刺、輸精管穿刺、睪丸精子萃取、睪丸衰竭定位。約 75% 的男性不孕症患者存在可識別或可治療的疾病。此外，幾乎所有男性不孕症患者都可以透過輔助生殖技術 (ART) 治療。因此，ART 和 IVF 的普及率不斷提升，很可能在未來幾年引領不孕檢測市場的新趨勢。

區域分析：不孕症檢測市場報告涵蓋北美、歐洲、亞太、南美和中美以及中東和非洲。

2022年，北美佔據了不孕症檢測市場的最大佔有率。該地區的成長動力源自於以下因素：不孕不育盛行率高、男女不孕症檢測意識增強、女性初次懷孕年齡上升，以及透過電商平台輕鬆取得不孕症檢測試劑盒。此外，吸菸和菸草使用率的上升預計將導致不孕不育病例增加，從而進一步推動市場成長。檢測意識的增強以及受多囊性卵巢症候群 (PCOS) 影響的女性人口不斷增加，也加速了市場擴張。

預計歐洲將佔據全球不孕症檢測市場的第三大佔有率。歐洲市場的成長得益於人們對不孕不育問題認知的提高、糖尿病患者的不斷成長、眾多市場參與者的存在以及政府在生育方面的舉措。根據歐洲人類生殖與胚胎學會的數據，預計2021年歐洲將有超過2,500萬人受到不孕症的影響。在歐洲，每個小學班級都會有一名兒童透過輔助生殖技術（ART）出生；在北歐國家，2%至7%的新生兒是透過ART技術出生的。西班牙憑藉其完善的法律架構、大量的不孕症專業人員、優良的設施和先進的醫療技術，成為不孕症治療的首選目的地。歐洲生育協會 (FE) 是 20 多個國家參與不孕症問題的歐洲協會的傘式組織，旨在改善不孕症患者的權利，在歐洲患者之間建立強大的跨境網路，提高社會對不孕症的認知，並加強生殖健康保護教育。

預計亞太地區不孕症檢測市場在預測期內將達到9.1%的最快成長率。這一區域成長歸因於受生活方式相關疾病影響的女性人數不斷增加、不孕症檢測產品開發投資的不斷增加，以及國內外企業對亞太地區不孕症檢測市場的日益關注。

不孕症檢測市場報告範圍：產業發展與未來機會：不孕症檢測市場預測可以幫助利害關係人規劃其成長策略。以下是市場領導企業報告的一些策略發展：

2023 年 7 月，全球領先的自我診斷測試公司 2San 與 Proov 合作，在美國中西部八個州的指定 Hy-Vee 門市推出了獨家、方便用戶使用的家用生育測試。 2022 年 1 月，著名的生育和家庭建設護理提供者 Kindbody 推出了其消費產品部門 Kind at Home，旨在為個人的整個生殖旅程提供支持，首先是針對男性和女性的方便用戶使用的家用生育激素測試。 2021 年 12 月，Carrot Fertility 推出了一款新套件，旨在幫助個人在家中監測生育激素和相關生物標記，提供全面的生育健康狀況視圖，並支持在家中舒適地進行主動干預。競爭格局和主要公司：不孕不育測試市場報告中介紹的主要公司包括默克集團、寶潔、bioMerieux SA、Alere Inc.、Babystart Ltd.、bioZhena Corporation、Quidel Corporation、CENTOGENE NV、SCSA Diagnostics， Inc. 和 Boditech Med Inc. 這些公司專注於開發新技術、改進現有產品並擴大其全球的需求，

目錄

第1章：簡介

第 2 章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：不孕症檢測市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：不孕症檢測市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：不孕症檢測市場－全球市場分析

  • 不孕症檢測 - 全球市場概覽
  • 不孕症檢測－全球市場及2031年預測

第7章：不孕症檢測市場-收入分析-依類型，2021-2031

  • 概述
  • 女性不孕不孕檢測
  • 男性不孕症檢測

第 8 章：不孕症檢測市場 - 收入分析 - 依檢測試劑盒分類，2021-2031 年

  • 概述
  • 人類促卵泡激素（FSH）尿液檢測試劑盒
  • 人類絨毛膜促性腺激素（HCG）血液檢測試劑盒
  • 黃體生成素（LH）檢測試劑盒
  • 其他

第9章：不孕症檢測市場-收入分析-依樣本，2021-2031

  • 概述
  • 血
  • 尿
  • 其他

第 10 章：不孕症檢測市場 - 收入分析 - 按最終用戶，2021-2031 年

  • 概述
  • 醫院和診所
  • 生育中心
  • 居家護理

第 11 章：不孕症檢測市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 13 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 14 章：不孕症檢測市場 - 主要公司簡介

  • Merck KGaA
  • Procter & Gamble
  • bioMerieux SA
  • Alere Inc.
  • Babystart Ltd.
  • bioZhena Corporation
  • Quidel Corporation
  • SCSA Diagnostics, Inc.
  • CENTOGENE N.V.
  • Boditech Med Inc.

第 15 章：附錄

簡介目錄
Product Code: TIPHE100001421

The infertility testing market is anticipated to expand from US$ 500.29 million in 2024 to US$ 890.96 million by 2031, with an estimated CAGR of 8.6% during the period of 2025-2031.

Market Insights and Analyst View:The growth of the market is driven by the rising incidence of infertility among both men and women, along with advancements in infertility testing technologies. However, the market's expansion is hindered by a lack of awareness and the limitations of infertility testing kits.

Infertility, in the context of reproductive health, refers to a condition that does not impair physical functioning or pose a life-threatening risk, yet it can impact personal development and lead to frustration for individuals (both men and women). Approximately 50 to 80 million couples face infertility challenges at least once during their reproductive years. The prevalence of infertility varies between developing and developed nations. The World Health Organization (WHO) reports that one in six couples experiences infertility issues. Growing awareness of testing, coupled with lifestyle changes and unhealthy dietary trends contributing to infertility and gynecological disorders, is driving the expansion of the infertility testing market. Additionally, advancements in ovulation monitoring technologies are further propelling market growth. Increased tobacco and smoking consumption is expected to raise infertility rates, thereby increasing the demand for infertility testing. Furthermore, heightened awareness of fertility, the rising number of women affected by PCOS, the growing demand for self-testing and remote monitoring among both genders, and the introduction of innovative products are likely to create opportunities for the infertility testing market in the forecast period.

Growth Drivers:Rising Incidence of Infertility in Men and Women Fuels Market Growth

Male infertility is a widespread issue globally, with varying prevalence across regions. The WHO indicates that approximately 20% of infertile couples have male-related infertility issues, while 30% of couples face infertility challenges due to both partners. Key factors contributing to male infertility include low hormone levels produced by the pituitary gland, deficiencies in semen and its quality, sexual dysfunctions affecting semen entry into the vaginal canal, and the presence of sperm antibodies. Varicocele, an enlarged vein in the testicle, is the most common cause of low sperm count, affecting about 40% of men with infertility issues, according to the US Department of Health and Human Services. The increase in male infertility cases is driving the demand for infertility testing.

Globally, fertility rates are declining due to various factors, including delayed marriages and age-related infertility. The WHO estimated that in 2020, there were around 128.5 million new chlamydia infections among adults aged 15-49 worldwide, with a prevalence of 4.0% in women and 2.5% in men. The Centers for Disease Control and Prevention (CDC) reports that about 10% of women (6.1 million) aged 15 to 44 in the US experience difficulties in conceiving or maintaining pregnancy. Consequently, the declining fertility rates are driving the demand for infertility testing to identify the causes of infertility in both men and women, thus propelling market growth.

Strategic Insights

Report Segmentation and Scope:The "infertility testing market analysis" has been conducted by examining the following segments: type, test kits, sample, and end user.

Segmental Analysis:The infertility testing market is divided into male infertility testing and female infertility testing segments. The female infertility testing segment held a larger market share in 2022, while the male infertility testing segment is expected to achieve a higher CAGR of 9.2% during the forecast period. Factors such as increased stress, obesity, smoking, and alcohol consumption contribute to male infertility. Additionally, rising awareness about infertility, increased R&D spending, initiatives by key players to launch new products, and changing lifestyles are driving growth in the male infertility testing segment.

In terms of test kits, the infertility testing market is categorized into human follicular stimulating hormone (FSH) test kits, human chorionic gonadotropin (HCG) hormone test kits, luteinizing hormone (LH) test kits, and others. The human follicular stimulating hormone (FSH) test kits segment held the largest market share in 2022 and is projected to record the highest CAGR of 9.2% during the forecast period. FSH test kits measure the concentration of FSH hormone in the blood, which is crucial for assessing fertility issues, menopause, and sexual development problems. FSH regulates the menstrual cycle in women and sperm production in men, making it an essential diagnostic tool for reproductive health. Furthermore, advancements in biosimilar FSH products, regulatory approvals, and technological innovations in FSH kit production are expected to drive global market growth.

By sample type, the infertility testing market is segmented into blood, urine, and others. The blood segment held the largest market share in 2022 and is anticipated to achieve the highest CAGR of 9.1% during the forecast period. Infertility tests typically involve blood tests to measure key hormones, with different tests required for men and women based on their specific situations. In January 2021, health startup Yesmom launched Asia's first at-home female fertility blood test kits, enabling women to prioritize their reproductive health conveniently.

By end user, the infertility testing market is divided into hospitals & clinics, fertility centers, and homecare. The homecare segment held the largest market share in 2022 and is expected to register the highest CAGR of 9.0% during the forecast period. This growth is attributed to patients' preference for self-monitoring health conditions, easy access to fertility testing kits via e-commerce platforms, the availability of user-friendly devices, and a growing desire for confidentiality regarding test results.

Adoption of Assisted Reproductive Technologies (ART) and In Vitro Fertilization (IVF) to Boost Infertility Testing Market

Increasing awareness of infertility is likely to drive demand for IVF and ART treatments in the coming years. The introduction of advanced intra-cytoplasmic sperm injection techniques and rising awareness of medicinal and surgical IVF procedures are expected to propel the infertility testing market during the forecast period. According to UCSF Health, approximately 10% of infertility cases are attributed to unknown causes, while 30% are due to issues in male and female partners.

Common procedures for men include intracytoplasmic sperm injection (ICSI), epididymal aspirations, vasal aspiration, testicular sperm extraction, and mapping of failing testes. About 75% of men with male factor infertility have identifiable or treatable conditions. Moreover, nearly all men with male factor infertility can be treated with ARTs. Therefore, the increasing adoption of ART and IVF is likely to introduce new trends in the infertility testing market in the coming years.

Regional Analysis:The infertility testing market report encompasses North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America accounted for the largest share of the infertility testing market. The growth in this region is driven by the high prevalence of infertility, increased awareness of infertility testing among both genders, the rising age of first pregnancies among women, and the easy availability of infertility test kits through e-commerce platforms. Additionally, the rising rates of smoking and tobacco use are expected to contribute to increased infertility cases, further propelling market growth. Growing awareness of testing and the increasing female population affected by PCOS are also accelerating market expansion.

Europe is projected to hold the third-largest share of the global infertility testing market. The growth in the European market is fueled by heightened awareness of infertility issues, a growing diabetic population, and the presence of numerous market players along with government initiatives related to fertility. According to the European Society of Human Reproduction and Embryology, infertility was estimated to affect over 25 million people in Europe in 2021. In Europe, one child per primary school class is born through assisted reproductive technologies (ART), and in Nordic countries, between 2% and 7% of births result from ART. Spain is a preferred destination for infertility treatment due to its progressive legal framework, high number of infertility professionals, excellent facilities, and advanced medical technologies. Fertility Europe (FE) is the umbrella organization for European associations involved in infertility issues across over 20 countries, aiming to improve the rights of those affected by infertility, foster a strong cross-border network among European patients, promote social awareness about infertility, and enhance education in reproductive health protection.

The Asia Pacific infertility testing market is expected to experience the fastest growth rate of 9.1% during the forecast period. This regional growth is attributed to the increasing number of women affected by lifestyle-related disorders, rising investments in the development of infertility testing products, and a heightened focus from both international and domestic players on the Asia Pacific infertility testing market.

Infertility Testing Market Report ScopeIndustry Developments and Future Opportunities:The infertility testing market forecast can assist stakeholders in planning their growth strategies. Below are some strategic developments reported by leading players in the market:

In July 2023, 2San, a global leader in self-diagnostic testing, partnered with Proov to launch exclusive, user-friendly at-home fertility tests at select Hy-Vee stores across eight Midwestern states.In January 2022, Kindbody, a prominent fertility and family-building care provider, launched Kind at Home, its consumer products division aimed at supporting individuals throughout their reproductive journey, starting with user-friendly home fertility hormone tests for both women and men.

In December 2021, Carrot Fertility introduced a new kit designed to help individuals monitor fertility hormones and related biomarkers at home, providing a comprehensive view of fertility health and enabling proactive interventions from the comfort of home.

Competitive Landscape and Key Companies:Key companies profiled in the infertility testing market report include Merck KGaA, Procter & Gamble, bioMerieux SA, Alere Inc., Babystart Ltd., bioZhena Corporation, Quidel Corporation, CENTOGENE N.V., SCSA Diagnostics, Inc., and Boditech Med Inc. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the growing consumer demand worldwide.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Infertility Testing Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Infertility Testing Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Infertility Testing Market - Global Market Analysis

  • 6.1 Infertility Testing - Global Market Overview
  • 6.2 Infertility Testing - Global Market and Forecast to 2031

7. Infertility Testing Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 7.1 Overview
  • 7.2 Female Infertility Testing
  • 7.3 Male Infertility Testing

8. Infertility Testing Market - Revenue Analysis (USD Million) - By Test Kits, 2021-2031

  • 8.1 Overview
  • 8.2 Human Follicular Stimulating Hormone (FSH) Urine Test Kits
  • 8.3 Human Chorionic Gonadotropin (HCG) Hormone Blood Test Kits
  • 8.4 Luteinizing Hormone (LH) Test Kits
  • 8.5 Others

9. Infertility Testing Market - Revenue Analysis (USD Million) - By Sample, 2021-2031

  • 9.1 Overview
  • 9.2 Blood
  • 9.3 Urine
  • 9.4 Others

10. Infertility Testing Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals & Clinics
  • 10.3 Fertility Centers
  • 10.4 Homecare

11. Infertility Testing Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Infertility Testing Market Overview
    • 11.1.2 North America Infertility Testing Market Revenue and Forecasts to 2031
    • 11.1.3 North America Infertility Testing Market Revenue and Forecasts and Analysis - By Type
    • 11.1.4 North America Infertility Testing Market Revenue and Forecasts and Analysis - By Test Kits
    • 11.1.5 North America Infertility Testing Market Revenue and Forecasts and Analysis - By Sample
    • 11.1.6 North America Infertility Testing Market Revenue and Forecasts and Analysis - By End User
    • 11.1.7 North America Infertility Testing Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Infertility Testing Market
        • 11.1.7.1.1 United States Infertility Testing Market, by Type
        • 11.1.7.1.2 United States Infertility Testing Market, by Test Kits
        • 11.1.7.1.3 United States Infertility Testing Market, by Sample
        • 11.1.7.1.4 United States Infertility Testing Market, by End User
      • 11.1.7.2 Canada Infertility Testing Market
        • 11.1.7.2.1 Canada Infertility Testing Market, by Type
        • 11.1.7.2.2 Canada Infertility Testing Market, by Test Kits
        • 11.1.7.2.3 Canada Infertility Testing Market, by Sample
        • 11.1.7.2.4 Canada Infertility Testing Market, by End User
      • 11.1.7.3 Mexico Infertility Testing Market
        • 11.1.7.3.1 Mexico Infertility Testing Market, by Type
        • 11.1.7.3.2 Mexico Infertility Testing Market, by Test Kits
        • 11.1.7.3.3 Mexico Infertility Testing Market, by Sample
        • 11.1.7.3.4 Mexico Infertility Testing Market, by End User
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East & Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East & Africa
  • 11.5 South & Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South & Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Infertility Testing Market - Key Company Profiles

  • 14.1 Merck KGaA
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Procter & Gamble
  • 14.3 bioMerieux SA
  • 14.4 Alere Inc.
  • 14.5 Babystart Ltd.
  • 14.6 bioZhena Corporation
  • 14.7 Quidel Corporation
  • 14.8 SCSA Diagnostics, Inc.
  • 14.9 CENTOGENE N.V.
  • 14.10 Boditech Med Inc.

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud